Raymond James & Associates Has $3.66 Million Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Raymond James & Associates reduced its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 14.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 178,254 shares of the company’s stock after selling 29,041 shares during the period. Raymond James & Associates owned about 0.18% of Intellia Therapeutics worth $3,663,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of NTLA. Vanguard Group Inc. lifted its stake in Intellia Therapeutics by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock valued at $250,168,000 after purchasing an additional 746,263 shares during the last quarter. ARK Investment Management LLC raised its holdings in Intellia Therapeutics by 5.5% in the 2nd quarter. ARK Investment Management LLC now owns 11,595,789 shares of the company’s stock valued at $259,514,000 after acquiring an additional 606,507 shares during the period. Federated Hermes Inc. raised its holdings in Intellia Therapeutics by 19.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after acquiring an additional 371,189 shares during the period. Opaleye Management Inc. raised its holdings in Intellia Therapeutics by 157.6% in the 1st quarter. Opaleye Management Inc. now owns 255,000 shares of the company’s stock valued at $7,015,000 after acquiring an additional 156,000 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Intellia Therapeutics by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after acquiring an additional 98,865 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NTLA. Stifel Nicolaus lowered their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday, September 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $54.00 price target on shares of Intellia Therapeutics in a report on Thursday, September 19th. Robert W. Baird lowered their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Chardan Capital lowered their target price on shares of Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Finally, Citigroup decreased their price objective on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $59.13.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $14.81 on Monday. The firm has a market cap of $1.50 billion, a PE ratio of -2.70 and a beta of 1.81. The firm’s fifty day moving average is $19.87 and its 200-day moving average is $22.43. Intellia Therapeutics, Inc. has a 52 week low of $13.95 and a 52 week high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The firm had revenue of $7.00 million for the quarter, compared to the consensus estimate of $19.68 million. The business’s revenue for the quarter was down 48.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.40) EPS. Sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.21 EPS for the current year.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the transaction, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.20% of the stock is owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.